Nanomedicine for Treating Major Brain Diseases: Advances and Future Directions
Molecular Pharmaceutics · 04.08.2025 · 22 (8) · 4413-4434
DOI: 10.1021/acs.molpharmaceut.5c00277 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, online erschienen am 30.06.2025. Verfasst von Girisha Sagar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, College of Pharmaceutical Sciences, Dayananda Sagar University, Devarakaggalahalli, Harohalli, Kanakapura Road, Bengalur…. Hauptthemen laut MEDLINE: Nanomedicine, Brain Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 178 Literaturangaben.
Abstract (Originalsprache)
Traditional drug delivery systems lack target specificity. Various macromolecules, which are useful to treat central nervous system (CNS) diseases, have failed in clinical trials. This is because the molecules fail to cross the blood-brain barrier (BBB) effectively. The diseases of the brain are a major cause of disability and death. Various brain diseases affect 3.4 billion people worldwide. Nanomedicine, the medical application of nanotechnology for the diagnosis and treatment of diseases, improves drugs' solubility, stability, bioavailability, safety, and therapeutic efficacy. Site-specific ligand conjugated nanomedicine increases the target-specificity of nanomedicine toward specific receptors or determinants and delivers the drugs to the target organ. Nanomedicine provides better patient care while minimizing side effects and treatment cost. Further, it has the ability to change the traditional way of diagnosing and treating diseases. This review discusses recent advances in the usefulness of nanomedicine to treat major brain diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and stroke. The article also addresses the challenges in the development of nanoformulation and associated nanotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, College of Pharmaceutical Sciences, Dayananda Sagar University, Devarakaggalahalli, Harohalli, Kanakapura Road, Bengaluru 562112, Karnataka, India.
- Department of Pharmacology, College of Pharmaceutical Sciences, Dayananda Sagar University, Devarakaggalahalli, Harohalli, Kanakapura Road, Bengaluru 562112, Karnataka, India.
- Department of Pharmaceutical Chemistry, College of Pharmaceutical Sciences, Dayananda Sagar University, Devarakaggalahalli, Harohalli, Kanakapura Road, Bengaluru 562112, Karnataka, India.
ORCID-Profile: Barnabas Wilson
Zitieren
APA
Sagar, G., Wilson, B., Kannoth Mukundan, G., Divekar, K., & Jenita, J. L. (2025). Nanomedicine for Treating Major Brain Diseases: Advances and Future Directions. Molecular Pharmaceutics, 22(8), 4413-4434. https://doi.org/10.1021/acs.molpharmaceut.5c00277
Vancouver
Sagar G, Wilson B, Kannoth Mukundan G, Divekar K, Jenita JL. Nanomedicine for Treating Major Brain Diseases: Advances and Future Directions. Molecular Pharmaceutics. 2025;22(8):4413-4434. doi:10.1021/acs.molpharmaceut.5c00277
BibTeX
@article{Sagar2025,
author = {Sagar, Girisha and Wilson, Barnabas and Kannoth Mukundan, Geetha and Divekar, Kalpana and Jenita, Josephine Leno},
title = {Nanomedicine for Treating Major Brain Diseases: Advances and Future Directions},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {8},
pages = {4413--4434},
doi = {10.1021/acs.molpharmaceut.5c00277}
}
EUVIMED